Obesity is a global epidemic and a major cause of morbidity and mortality because it increases the risk for comorbidities, ...
Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...
As a proof of concept, the engineers then used the same system to convert acetyl-CoA into malate, a commercially valuable ...
Iranian researchers discovered new bacteria, Bacillus spizizenii, that produce large amounts of a starch-breaking enzyme.
BTech in Chemical Engineering has been offered in India since 1921. However, BTech in Chemical and Biochemical Engineering is ...
Hansa Biopharma AB, ("Hansa" or "the Company"), , today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imlifidase. The Company is ...
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types ...
Researchers have captured real-time "molecular movies" showing how an enzyme changes shape during catalysis. The study was ...
92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent ...
Subject to TSX Venture Exchange (“ TSXV ”) approval, NurExone has engaged Russo Partners LLC, a New York–based strategic ...
The global market is estimated at USD 25,900.5 million in 2025 and is forecast to reach USD 64,187.5 million by 2035, ...
Discover why Denali Therapeutics Inc. earns a Strong Buy with FDA-priority drugs, solid pipeline, and a strong cash position.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback